Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
CA 2418951 A1 · Owner: Magnesium Diagnostics, Inc. · Inventors: Wells, Ibert Clifton
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders such as for example a , frequently occurring type of essential hypertension which are critically , associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of distributed trans trans , 1,3-butadienes, 1, 3-disubstituted perhydrobutadienes 1,2-disubstituted trans , ethylenes and 1,2-disubstituted ethanes and disubstituted propanes each of , which embodies, in common, the unique structural feature essential for the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 9, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 9, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 9, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.